BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 27114592)

  • 1. European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis.
    Sachchithanantham S; Roussel M; Palladini G; Klersy C; Mahmood S; Venner CP; Gibbs S; Gillmore J; Lachmann H; Hawkins PN; Jaccard A; Merlini G; Wechalekar AD
    J Clin Oncol; 2016 Jun; 34(17):2037-45. PubMed ID: 27114592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AL amyloidosis associated with IgM monoclonal protein: a distinct clinical entity.
    Palladini G; Russo P; Bosoni T; Sarais G; Lavatelli F; Foli A; Bragotti LZ; Perfetti V; Obici L; Bergesio F; Albertini R; Moratti R; Merlini G
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):80-3. PubMed ID: 19362981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective analysis of clinical features and treatment outcome in 21 patients with immunoglobulin M-related light-chain amyloidosis in Japan: a study from the Amyloidosis Research Committee.
    Fuchida SI; Ogura M; Ishida T; Hata H; Handa H; Katoh N; Nakaseko C; Sunami K; Katayama Y; Nobata H; Oshiro K; Iida S; Sekijima Y; Naiki H; Shimazaki C
    Int J Hematol; 2023 Oct; 118(4):443-449. PubMed ID: 37515656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.
    Palladini G; Dispenzieri A; Gertz MA; Kumar S; Wechalekar A; Hawkins PN; Schönland S; Hegenbart U; Comenzo R; Kastritis E; Dimopoulos MA; Jaccard A; Klersy C; Merlini G
    J Clin Oncol; 2012 Dec; 30(36):4541-9. PubMed ID: 23091105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal IgM-related AL amyloidosis.
    Milani P; Merlini G
    Best Pract Res Clin Haematol; 2016 Jun; 29(2):241-248. PubMed ID: 27825470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.
    Wechalekar AD; Schonland SO; Kastritis E; Gillmore JD; Dimopoulos MA; Lane T; Foli A; Foard D; Milani P; Rannigan L; Hegenbart U; Hawkins PN; Merlini G; Palladini G
    Blood; 2013 Apr; 121(17):3420-7. PubMed ID: 23479568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical presentation and treatment responses in IgM-related AL amyloidosis.
    Sissoko M; Sanchorawala V; Seldin D; Sworder B; Angelino K; Broce M; Berk J; Sloan JM
    Amyloid; 2015; 22(4):229-35. PubMed ID: 26488936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed and Relapsed Amyloid Light Chain Amyloidosis: A Single-Center Experience.
    Jimenez-Zepeda VH; Duggan P; Neri P; Bahlis NJ
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e79-84. PubMed ID: 27101985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IgM amyloidosis: clinical features in therapeutic outcomes.
    Gertz MA; Buadi FK; Hayman SR
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):146-8. PubMed ID: 21454218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The importance of cardiac bio-marker assay for the stratification and monitoring of AL amyloidosis patients -  single center experience].
    Pika T; Lochman P; Vymětal J; Metelka R; Flodr P; Minařík J; Látalová P; Zapletalová J; Bačovský J; Sčudla V
    Vnitr Lek; 2013 Sep; 59(9):776-81. PubMed ID: 24073949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome.
    Wechalekar AD; Lachmann HJ; Goodman HJ; Bradwell A; Hawkins PN; Gillmore JD
    Blood; 2008 Nov; 112(10):4009-16. PubMed ID: 18708629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.
    Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kumar SK; Kapoor P; Kourelis TV; Hogan WJ; Gertz MA
    Blood Adv; 2018 Apr; 2(7):769-776. PubMed ID: 29615413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Value of Left Ventricular
    Clerc OF; Datar Y; Cuddy SA; Bianchi G; Taylor A; Benz DC; Robertson M; Kijewski MF; Jerosch-Herold M; Kwong RY; Ruberg FL; Liao R; Di Carli MF; Falk RH; Dorbala S
    medRxiv; 2023 Sep; ():. PubMed ID: 37745589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.
    Kumar S; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Colby C; Laumann K; Zeldenrust SR; Leung N; Dingli D; Greipp PR; Lust JA; Russell SJ; Kyle RA; Rajkumar SV; Gertz MA
    J Clin Oncol; 2012 Mar; 30(9):989-95. PubMed ID: 22331953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients.
    Terrier B; Jaccard A; Harousseau JL; Delarue R; Tournilhac O; Hunault-Berger M; Hamidou M; Dantal J; Bernard M; Grosbois B; Morel P; Coiteux V; Gisserot O; Rodon P; Hot A; Elie C; Leblond V; Fermand JP; Fakhouri F
    Medicine (Baltimore); 2008 Mar; 87(2):99-109. PubMed ID: 18344807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes for patients with systemic light chain amyloidosis and Mayo stage 3B disease.
    Theodorakakou F; Briasoulis A; Fotiou D; Petropoulos I; Georgiopoulos G; Lama N; Kelekis N; Repasos E; Migkou M; Stamatelopoulos K; Dimopoulos MA; Kastritis E
    Hematol Oncol; 2023 Oct; 41(4):725-732. PubMed ID: 36974438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival.
    Basset M; Milani P; Foli A; Nuvolone M; Benvenuti P; Nanci M; Fabris F; Bellofiore C; Merlini G; Palladini G
    Blood; 2022 Nov; 140(18):1964-1971. PubMed ID: 35772003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical presentation and prognosis of light-chain amyloidosis patients with unmeasurable free light-chain levels.
    Qiu Y; Zhang CL; Shen KN; Su W; Feng J; Zhang L; Cao XX; Li J
    Ann Hematol; 2018 Dec; 97(12):2465-2470. PubMed ID: 30056579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis.
    Sidiqi MH; Buadi FK; Dispenzieri A; Warsame R; Lacy MQ; Dingli D; Leung N; Gonsalves WI; Kapoor P; Kourelis TV; Hogan WJ; Kumar SK; Gertz MA
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):e108-e111. PubMed ID: 30529461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features.
    Sidana S; Larson DP; Greipp PT; He R; McPhail ED; Dispenzieri A; Murray DL; Dasari S; Ansell SM; Muchtar E; Gonsalves WI; Kourelis TV; Ramirez-Alvarado M; Kapoor P; Rajkumar SV; Lacy MQ; Buadi FK; Leung N; Kyle RA; Kumar SK; King RL; Gertz MA
    Leukemia; 2020 May; 34(5):1373-1382. PubMed ID: 31780812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.